David Sher
@DavidSherMD
"Ultimately, the secret of quality is love. You have to love your patient, you to have to love your profession, you have to love your G-d." Avedis Donabedian
I recently saw a patient 9 years following early-stage glottic larynx SAbR (on our original CyberKnife trial). The images below represent the typical endoscopic appearance. Our G-FORCE phase II RCT (LT-SAbR versus whole larynx) is now ~ 33% accrued! clinicaltrials.gov/study/NCT06080…
The Force was with us today @UTSW_RadOnc! We treated our first HANSOLO patient using Ethos: Head And Neck radiotherapy with Simulation Omitted and setup and pLanning Online. Patient needed emergent radiotherapy to control bleeding but may receive definitive treatment later,…
Re: impact of more sensitive NGS assays. We agree. Preliminary results from our Clear-HPVca Trial (NCT NCT06730412) were highly promising (presented at ASCO 2024- ascopubs.org/doi/10.1200/JC…) Final analysis being completed and hope to have results out soon.
See our commentary on Routman et al here: jamanetwork.com/journals/jamao… @JAMAOto
DART 2, which was based upon this work, should finish accrual Q2 2026, so more data on ctDNA-personalized de-escalation will be available in the near future. Primary manuscript for DART should be out in the next two months as well.
This is very nice work and has important implications for the use of NavDX (ctHPVDNA by ddPCR) to determine postoperative treatment. During the Mayo DART trial, ctDNA was drawn a median of 22 days after surgery, with 17/140 (12.1%) positive. ALL of these patients then received…
This is very nice work and has important implications for the use of NavDX (ctHPVDNA by ddPCR) to determine postoperative treatment. During the Mayo DART trial, ctDNA was drawn a median of 22 days after surgery, with 17/140 (12.1%) positive. ALL of these patients then received…
Patients who are post-op minimal residual disease (MRD)+ are at a higher risk of recurrence; MRD status approximately 2-3 weeks post-op may be useful in addition to pathologic factors to select patient candidacy for de-escalation. ja.ma/4eOr1l0 @LindaXYinMD
Very thoughtful take in this article. One additional comment: if there is any one discipline in US radiation oncology that is disappearing over the next 5 years, it is the dosimetrist/treatment planner. Auto-planning will essentially render this position close to obsolete, with…
#radonc sciencedirect.com/science/articl… Thanks to Dr. Chhabra, and team for spearheading this important discussion. And thanks to the usual suspects that speak up for the health of the field and young doctors. @DrChowdharyMD, @CShahMD, @JamesBatesMD
Excited to share our latest work in Advances in Radiation Oncology! 🚀 We compared outcomes of 5-fraction adaptive MRI-guided RT for newly diagnosed glioblastoma vs. 15- & 30-fraction regimens using propensity score matching. 📄doi.org/10.1016/j.adro…
Rising PGY-5s and anyone interested, we have a 5th HN rad onc position @MoffittNews. If interested in joining a busy team, including me, Dr. M Echevarria, @BeekeepRadOnc, and @RadOncDoc_Niema, reach out and can chat about the position.
Excellent work here, with successful results consistent with the published literature on 40 Gy (or less) to the elective neck.
Led by Drs. Zakeri & @imrtlee, we report early @MSK_RadOnc exp w/ 40 Gy ENI + CCRT for larynx, HPX, p16- OPX + CUP, 97.3% platinum, no uninvolved 1B+5 ☑️73 pts, f/u 23 months ✅no solitary elective failures, all LRF include 70 Gy failures ✅good QoL 👉 shorturl.at/CKA6W
Is anyone surprised that CM816 is the only pure neoadjuvant phase 3 trial for resectable solid organ disease?!? Now that we know the durable effects of checkpoint blockade, how can we ignore these data in new trial designs across the spectrum of solid organ tumors?
Why is CM816 so important? After @FordePatrick beautiful presentation of these revolutionary data, let’s dig into why this unique trial should shake up our vision for oncology research…
This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.